News

Results Found (485)
January 22, 2008
Protalix BioTherapeutics Extends Research Agreement With Yissum, Based on...

The Acetylcholinesterase (AChE) Program is being conducted

under the agreement the Company entered into with Yissum Research and

Development Company, the technology transfer arm of the Hebrew University of

Jerusalem, Israel, and the Boyce...

January 22, 2008
Israel's most powerful woman in biotech

Israel 21c portraying Nava Swersky Sofer, Yissum's President & CEO 

January 13, 2008
Yissum spin-off Biocancell to begin Phase IIb trial for bladder cancer drug

The FDA approved the trial at 5 Israeli hospitals and one in Arizona. 

 

January 9, 2008
New Alzheimer's drug to go commercial, thanks to Israeli research

Yissum and Eucalyptus Biosciences Sign Licensing Agreement for the Development of a Small Molecule for the Treatment of Neurodegenerative Diseases

December 28, 2007
Ivory Towers? Not!

Israel's Universities and institutes are all about developing and selling technology 

December 20, 2007
Yissum spins-off Nanolymf, a new company formed for drug delivery technology

Jerusalem-based Yissum has formed a spin-off company - Nanolymf, which will

be dedicated to advancing a nanotechnology controlled-release drug delivery platform.

December 10, 2007
Amarin buys Ester Neurosciences in $30m deal

The Israeli company is developing treatments for various neurological diseases based on a technology licensed from Yissum

December 8, 2007
Drugs and vaccines by 'special delivery'

One of Israel's leading biochemists, Prof. Yechezkel Barenholz of the Hebrew University's Hadassah Medical School, has used liposomes to design better drug delivery systems that extend and improve the lives of cancer patients around the...

December 5, 2007
Biomed industry leaders discuss funding opportunities at the Milken...
December 2, 2007
Yissum partner Medgenics raises ₤3.3m in AIM IPO

US-Israeli biopharmaceutical start-up Medgenics Inc. raised a gross ₤3.3 million in its IPO on London’s Alternative Investment Market (AIM) on Thursday at a company value of ₤10.4 million, after money. The company, which is based on Yissum's...

November 26, 2007
Yissum spin-off Target-In: Israeli 'guided missiles' induce cancer cells to...

People call what Target-In is doing 'guided missiles', and in a way that's exactly what the company's technology is: a guided missile that can recognize and kill inflamed cells from tumors and other diseases. But Target-In's technology is more...

November 15, 2007
Yissum licenses Anti-Cancer Compound BL-4060 to BioLineRx

BioLineRx today announced that it has signed a worldwide exclusive

license agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem, and Hadasit, the technology transfer company of Hadassah medical...